Stock analysts at StockNews.com started coverage on shares of Protalix BioTherapeutics (NYSE:PLX – Get Rating) in a report issued on Thursday. The firm set a “hold” rating on the stock.
Protalix BioTherapeutics Stock Performance
About Protalix BioTherapeutics
Protalix Biotherapeutics, Inc is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Carmiel, Israel.
Recommended Stories
- Get a free copy of the StockNews.com research report on Protalix BioTherapeutics (PLX)
- 5 Best Bank ETFs to Buy Now
- How to Invest in Telehealth and Telemedicine Stocks
- Target’s Guidance Looms Over The MarketÂ
- Want Clean Energy? Siemens May Be Pointing To A Breakout
- Up Over 2,600% in 5 Years, Wall Street Still Calls Celsius a Buy
Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
